Pharming (PHAR) Research & Development (2020 - 2025)
Historic Research & Development for Pharming (PHAR) over the last 6 years, with Q3 2025 value amounting to -$2.2 million.
- Pharming's Research & Development rose 8918.01% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.4 million, marking a year-over-year decrease of 208.67%. This contributed to the annual value of $83.1 million for FY2024, which is 2065.33% up from last year.
- According to the latest figures from Q3 2025, Pharming's Research & Development is -$2.2 million, which was up 8918.01% from -$44.8 million recorded in Q2 2025.
- Pharming's Research & Development's 5-year high stood at $35.8 million during Q4 2021, with a 5-year trough of -$83.1 million in Q4 2024.
- Over the past 5 years, Pharming's median Research & Development value was -$18.5 million (recorded in 2024), while the average stood at -$22.5 million.
- Per our database at Business Quant, Pharming's Research & Development crashed by 13880654.21% in 2022 and then soared by 8918.01% in 2025.
- Pharming's Research & Development (Quarter) stood at $35.8 million in 2021, then crashed by 130.44% to -$10.9 million in 2022, then crashed by 532.24% to -$68.9 million in 2023, then dropped by 20.65% to -$83.1 million in 2024, then surged by 97.3% to -$2.2 million in 2025.
- Its Research & Development was -$2.2 million in Q3 2025, compared to -$44.8 million in Q2 2025 and -$21.1 million in Q1 2025.